כל המחקרים
פעיל אך לא מגייסשלב 3התערבותי

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

Researchers are studying a medicine called omaveloxolone (also known as SKYCLARYS®) for children and teenagers aged 2 to 15 who have Friedreich’s Ataxia. This medicine is already approved for adults with Friedreich’s Ataxia, but we need to understand how it affects younger people. The main goals are to find out if the medicine helps with symptoms, if it's safe to use, and how it's handled by the body in growing children and teens. Participants will either receive the medicine or a dummy pill (placebo) for about a year, and then everyone will receive the medicine for two more years. This will help doctors learn more about this important treatment for younger patients.

במבט חטוף

סטטוס
פעיל אך לא מגייס
שלב
שלב 3
נותן חסות
Biogen
יעד הרשמה
255
התחל
09 Jun 2025
השלמה משוערת
22 Nov 2029

על מה המחקר הזה?

Doctors are running a study to find out more about a medicine called omaveloxolone (also known as SKYCLARYS®). This medicine is already used by people aged 16 and over in the UK who have a condition called Friedreich’s Ataxia. However, we don't yet know if it's suitable or safe for younger children and teenagers with the same condition.

The main aims of this study are to see how omaveloxolone affects the symptoms of Friedreich’s Ataxia in younger people. We also want to understand if it's safe for them and if there are any side effects. Researchers will be looking at how the medicine works in the body and if it helps with daily activities, movement, and general well-being.

This research is important because it could help make omaveloxolone available to a younger age group, potentially improving their future. By carefully studying its effects, we can ensure that any treatment is both effective and safe for children and teenagers with Friedreich’s Ataxia.

נקודות עיקריות

  • This study is testing a medicine called omaveloxolone (SKYCLARYS®) for children and teenagers with Friedreich's Ataxia (FA).
  • It aims to see how it affects FA symptoms and if it's safe for those aged 2 to 15.
  • Participants will first receive either the medicine or a dummy pill, then all will receive the medicine for a longer period.
  • Regular clinic visits and phone calls will happen over up to 3 years to monitor health and progress.
  • Information from this study could help make treatment available to younger FA patients.

מי עשוי להיות זכאי?

To join this study, people need to be between 2 and 15 years old and have a confirmed diagnosis of Friedreich’s Ataxia. For those aged 7 to under 16, there's also a specific test of balance they need to meet.

However, some health conditions might mean someone can't take part. For example, if they have very high blood sugar levels (measured by a test called HbA1c), a particular heart marker (BNP) that's too high, or a heart function (ejection fraction) that's too low. People with serious heart conditions, other than a mild to moderate form often seen in Friedreich’s Ataxia, might also not be able to join.

There might be other reasons, not listed here, why someone can or cannot join. The study doctors will carefully check everyone's health to make sure it's safe for them to take part.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Are you between 2 and 15 years old?
  2. Have you been diagnosed with Friedreich’s Ataxia?
  3. If you are aged between 7 and 15, do you have a specific balance score as assessed by your doctor?
  4. Do you have any serious underlying heart conditions (apart from mild to moderate cardiomyopathy) that might prevent you from joining?
  5. Do you have very high blood sugar levels (HbA1c > 11%) or certain heart markers (BNP > 200, EF < 40%)?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to join, you'll first have a screening period of up to 4 weeks to check if the study is right for you. Then, for about one year (Part 1), you'll be randomly given either omaveloxolone or a dummy pill that looks the same but has no active medicine. Neither you, your doctor, nor the study staff will know which you are receiving. During this time, you'll have up to 9 visits to the clinic and one phone call. After about a month of finishing this part, you'll have a safety check by phone.

If you complete Part 1, you'll then move to Part 2 for about two more years, where everyone will receive omaveloxolone. You'll have up to 8 more clinic visits and one phone call. About a month after you stop taking the medicine in Part 2, you'll have a final follow-up phone call. In total, you could be in the study for up to 3 years, with a total of up to 17 clinic visits and 3 phone calls.

סיכונים ותועלות פוטנציאליים

Taking part in any medical study carries potential benefits and risks. For this study, potential benefits might include helping doctors learn more about treating Friedreich’s Ataxia in younger people, and you might receive a new treatment that could help with your symptoms. Risks could include experiencing side effects from the medicine, or changes to your overall health, including your heart, that may or may not be related to the study medicine. Throughout the study, your health will be carefully monitored. Remember, joining is completely voluntary, and you can withdraw from the study at any time without affecting your medical care.

Locations (34)

  • UCLA Neurology Outpatient Clinic at Westwood
    מיקוד מאומת
    לוס אנג'לס, ארצות הברית
  • Norman Fixel Institute for Neurological Diseases UF Health
    מיקוד מאומת
    גיינסוויל, ארצות הברית
  • USF Health Morsani College of Medicine Department of Neurology
    מיקוד מאומת
    טמפה, ארצות הברית
  • Children's Hospital of Philadelphia - Buerger Center for Advanced Pediatric Care - PIN
    מיקוד מאומת
    פילדלפיה, ארצות הברית
  • St. Jude Children's Research Hospital - PIN
    מיקוד מאומת
    Memphis, United States
  • CHKD's Health Center - South Campus - PIN
    מיקוד מאומת
    נורפוק, ארצות הברית
  • בית החולים לילדים סיאטל
    מיקוד מאומת
    סיאטל, ארצות הברית
  • Sydney Children's Hospital
    מיקוד מאומת
    Randwick, Australia
  • Murdoch Childrens Research Institute (MCRI)
    מיקוד מאומת
    Parkville, Australia
  • Universitätsklinikum Innsbruck
    מיקוד מאומת
    אינסברוק, אוסטריה
  • L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME
    מיקוד מאומת
    Brasília, Brazil
  • University of Campinas (UNICAMP) School of Medical Sciences
    מיקוד מאומת
    Campinas, Brazil

שאלות נפוצות

What is Friedreich’s Ataxia?

Friedreich’s Ataxia is a rare genetic condition that affects the nervous system, causing problems with movement, balance, and speech, and can also affect the heart.

What is omaveloxolone (SKYCLARYS®)?

It's a medicine already approved for adults with Friedreich's Ataxia. This study is looking at whether it's safe and helpful for children and teenagers.

מהו 'פלצבו'?

A placebo is a dummy pill that looks exactly like the study medicine but doesn't contain any active ingredients. It helps researchers compare the real medicine's effects.

האם אדע אם אני מקבל את התרופה האמיתית או את הפלצבו?

No, during the first part of the study, neither you, your doctor, nor the study staff will know whether you are receiving omaveloxolone or the placebo. This is called 'double-blind'.

כמה זמן אהיה במחקר?

You could be in the study for up to 3 years in total, including screening, the first part where you might get placebo or the medicine, and the second part where everyone gets the medicine.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.